Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 62-72 , January 2003

Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy

References 

  1. Ang KK. Altered fractionation trials in head and neck cancer. Semin Radiat Oncol. 1998;8:230–236
  2. Kaanders JH, Ang KK. Early Reactions as Dose-Limiting Factors in Radiotherapy. Semin Radiat Oncol. 1994;4:55–67
  3. Tubiana M, Eschwege F. Conformal radiotherapy and intensity-modulated radiotherapy—Clinical data. Acta Oncol. 2000;39:555–567
  4. Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002;12:20–25
  5. Weiss JF, Landauer MR. Radioprotection by antioxidants. Ann N Y Acad Sci. 2000;899:44–60
  6. Food and Drug Administration . Ethyol® (amifostine) for Injection. 1999;
  7. Komaki R, Lee JS, Kaplan B. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol. 2002;12:46–49
  8. Jatoi A, Thomas CR. Jr: Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Semin Radiat Oncol. 2002;12:62–67
  9. Movsas B. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Semin Radiat Oncol. 2002;12:40–45
  10. Werner-Wasik M, Axelrod RS, Friedland DP. Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Semin Radiat Oncol. 2002;12:34–39
  11. Zoberi I, Wasserman TH, Chao KS. A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers. Semin Radiat Oncol. 2002;12:14–17
  12. Small W. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: A review. Semin Radiat Oncol. 2002;12:68–74
  13. Trotti A. Toxicity antagonists in head and neck cancer. Semin Radiat Oncol. 1998;8:282–291
  14. Patt HM, Tyree EB, Straube RL. Cysteine protection against X irradiation. Science. 1949;110:213–214
  15. Hall EJ. Radioprotectors Radiobiology for the radiologist. In: Philadelphia, PA: Lippincott; 2000;p. 136–146
  16. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980;40:1519–1524
  17. Yuhas JM. Protective drugs in cancertherapy: optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys. 1982;8:513–517
  18. Hensley ML, Schuchter LM, Lindley C. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3355
  19. Shaw LM, Bonner H, Lieberman R. Pharmacokinetic profile of amifostine. Sem Oncol. 1999;23:18–22
  20. Utley JA, Seaver N, Newton GL. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Int J Radiat Oncol Biol Phys. 1984;10:1525–1528
  21. Washburn LC, Rafter JJ, Hayes RL. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res. 1976;66:100–105
  22. Millar JL, McElwain TJ, Clutterbuck RD. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol. 1982;5:321–328
  23. Savoye C, Swenberg C, Hugot S. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol. 1997;71:193–202
  24. Peters GJ, van der Vijg WJF. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): Preclinical aspects. Eur J Cancer. 1995;31A(suppl 1):S1–S7
  25. Travis EL. The oxygen dependence of protection by aminothiols: Implications for normal tissues and solid tumors. Int J Radiat Oncol Biol Phys. 1984;10:1495–1501
  26. Denekamp J, Michael BD, Rojas A. Radioprotection of mouse skin by WR-2721: the critical influence of oxygen tension. Int J Radiat Oncol Biol Phys. 1982;8:531–534
  27. Durand RE, Olive PL. Radiosensitization and radioprotection by BSO and WR-2721: The role of oxygenation. Br J Cancer. 1989;60:517–522
  28. Durand RE. Radioprotection by WR-2721 in vitro at low oxygen tensions: Implications for its mechanisms of action. Br J Cancer. 1983;47:387–392
  29. Sigdestad CP, Connor AM, Scott RM. The effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR2721) on intestinal crypt survival. II. Fission neutrons. Radiat Res. 1976;95:430–439
  30. Rasey JS, Nelson NJ, Mahler P. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. Radiat Res. 1984;97:598–607
  31. Shigematsu N, Schwartz JL, Grdina DJ. Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N"-(dithiodi-2,1-ethanediyl)bis-1,3-propanediamine (WR-33278). Mutagenesis. 1994;9:355–360
  32. Grdina DJ, Guilford WH, Sigdestad CP. Effects of radioprotectors on DNA damage and repair, proteins, and cell-cycle progression. Pharmacol Ther. 1988;39:133–137
  33. Woloschak GE, Paunesku T, Chang-Liu CM. Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res. 1995;55:4788–4792
  34. Grdina DJ, Kataoka Y, Basic I. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis. 1992;13:811–814
  35. Bohuslavizki KH, Klutmann S, Jenicke L. Radioprotection of salivary glands by S-2-(3-aminopropylamin)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model. Int J Radiat Oncol Biol Phys. 1999;45:181–186
  36. Mustoe TA, Pierce GF, Morishima C. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Clin Invest. 1991;87:694–703
  37. Rojas A, Stewart FA, Soranson JA. Fractionated studies with WR-2721: Normal tissues and tumour. Radiother Oncol. 1986;6:51–60
  38. Yuhas JM, Afzal SMF, Afzal V. Variation in normal tissue responsiveness to WR-2721. Int J Radiat Oncol Biol Phys. 1984;10:1537–1539
  39. Mori T, Nikado O, Sugahara T. Dephosporylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys. 1984;10:1529–1531
  40. Rojas A, Denekamp J. The influence of X ray dose level on normal tissue radioprotection by WR-2721. Int J Radiat Oncol Biol Phys. 1984;10:2351–2356
  41. Calabro-Jones PM, Fahey RC, Smoluk GD. Alkaline phosphatase promotes radioprotection and accumulation of WR- 1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med. 1985;47:23–27
  42. Thomson DC, Wyrick SD, Holbrook DJ. Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the fischer 344 rat bearing a fibrosarcoma. Cancer Res. 1995;55:2837–2846
  43. Blumberg AL, Nelson DF, Gramkowski M. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys. 1982;8:561–563
  44. Bourhis J, De Crevoisier R, Abdulkarim B. A randomised study of very accelerated radiotherapy with and without amifostine in advanced head and neck squmaous cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:1105–1108
  45. Bonner HS, Shaw LM. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol. 2002;42:166–174
  46. Koukourakis MI, Kyrias G, Kakolyris S. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226–2233
  47. Anne PR, Curran WJ. Jr: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002;12:18–19
  48. Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629–638
  49. Capizzi RL. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996;23(suppl 8):2–17
  50. Wasserman T. Radioprotective effects of amifostine. Semin Oncol. 1999;26(suppl 7):89–94
  51. Rojas A, Stewart FA, Denekamp J. Experimental radiotherapy with WR-2721 and misonidazole. Int J Radiat Oncol Biol Phys. 1982;8:527–530
  52. Clement JJ, Johnson RK. Influence of WR 2721 on the efficiacy of radiotherapy and chemotherapy in murine tumors. Int J Radiat Oncol Biol Phys. 1982;8:539–542
  53. Lowy RO, Baker DG. Effect of radioprotective drugs on the therapeutic ratio for a mouse tumor system. Acta Radiol Ther Phys Biol. 1973;12:425–433
  54. Milas L, Hunter N, Reid BO. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res. 1982;42:1888–1897
  55. Moulder JE, Lo PS, Fischer JJ. Effect of the radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat. Cancer Treat Rep. 1977;61:825–833
  56. Phillips TL, Kane L, Utley JF. Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer. 1973;32:528–535
  57. Utley JF, Phillips TL, Kane LJ. Differential radioprotection of euoxic and hypoxic mouse mammary tumors by a thiophosphate compound. Radiol. 1974;110:213–216
  58. Yuhas JM. Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). J Natl Cancer Ins. 1973;50:69–78
  59. Yuhas JM, Yurconic M, Kligerman MM. Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy. Radiat Res. 1977;70:433–443
  60. Yuhas JM, Storer JB. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst. 1969;42:331–335
  61. McChesney SL, Gillette EL, Dewhirst MW. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1986;12:1957–1963
  62. Yuhas JM. Efficacy testing of WR-2721 in Great Britain everything is black and white at the Gray lab. Int J Radiat Oncol Biol Phys. 1983;9:595–598
  63. Denekamp J, Stewart FA, Rojas A. Is the outlook grey for WR-2721 as a clinical radioprotector. Int J Radiat Oncol Biol Phys. 1983;9:1247–1249
  64. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector?. Radiother Oncol. 2000;57:113–118
  65. Wasserman TH, Brizel DM. Has the outlook improved for amifostine as a clinical radioprotector. Radiother Oncol. 2001;60:334–336
  66. Twentyman PR. Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse. Br J Cancer. 1983;47:57–63
  67. Chaplin DJ, Horsman MR. Tumor blood flow changes induced by chemical modifiers of radiation response. Int J Radiat Oncol Biol Phys. 1992;22:459–462
  68. Dische S, Chassagne D, Hope-Stone HF. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol. 1993;26:93–103
  69. Milas L, Hunter N, Ito H. Effect of tumor type, size and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys. 1984;10:41–48
  70. Rojas A, Stewart FA, Denekamp J. Interaction of misonidazole and WR-2721—II. Modification of tumour radiosensitization. Br J Cancer. 1983;47:65–72
  71. Mcdonald S, Meyerowitz C, Smudzin T. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys. 1994;29:747–754
  72. Bohuslavizki KH, Klutmann S, Brenner W. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol. 1998;16:3542–3549
  73. Brizel DM, Wasserman TH, Henke M. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  74. Wasserman T, Mackowiak JI, Brizel DM. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;48:1035–1039
  75. Buntzel J, Kuttner K, Frohlich D. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505–509
  76. Bennett CL, Lane D, Stinson T. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest. 2001;19:107–113
  77. Peters K, Mucke R, Hamann D. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?. Strahlenther Onkol. 1999;175(suppl 4):23–26
  78. Vacha P, Marx M, Engel A. Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlenther Onkol. 1999;175(suppl 4):18–22
  79. Antonadou D, Pepelassi M, Synodinou M. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  80. Antonadou D, Coliarakis N, Synodinou M. Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–922
  81. Mitsuhashi N, Takahashi I, Takahashi M. Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer. Int J Radiat Oncol Biol Phys. 1993;26:407–411
  82. Liu T, Liu Y, He S, Zhang Z. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer. 1992;69:2820–2825
  83. Rubin P, Johnston CJ, Williams JP. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995;33:99–109
  84. Herskind C, Bamberg M, Rodemann HP. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol. 1998;174(suppl 3):12–15
  85. Hill RP, Rodemann HP, Hendry JH. Normal tissue radiobiology: From the laboratory to the clinic. Int J Radiat Oncol Biol Phys. 2001;49:353–365
  86. Martin M, Lefaix J, Delanian S. TGF-beta 1 and radiation fibrosis: A master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys. 2000;47:277–290
  87. Lefaix JL, Delanian S, Vozenin MC. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: An experimental study. Int J Radiat Oncol Biol Phys. 1999;43:839–847
  88. Moulder J. Pharmacological intervention to prevent or ameliorate chronic radiation injuries. Semin Radiat Oncol. 2002;
  89. Stephens LC, Schultheiss TE, Price RE. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer. 1991;67:1539–1543
  90. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol. 1998;16:3179–3190
  91. Dittmann KH, Gueven N, Mayer C. The presence of wild-type TP53 is necessary for the radioprotective effect of the Bowman-Birk proteinase inhibitor in normal fibroblasts. Radiat Res. 1998;150:648–655
  92. Dorr W, Noack R, Spekl K. Modification of oral mucositis by keratinocyte growth factor: Single radiation exposure. Int J Radiat Biol. 2001;77:341–347

☆ Address reprint requests to Christian Nicolaj Andreassen, MD, Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebroggade 44, DK 8000 Aarhus C, Denmark.

PII: S1053-4296(03)50009-1

doi: 10.1053/srao.2003.50006

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 62-72 , January 2003

Article Tools

* Image Usage & Resolution